From Mechanisms to Action: Exploring the Therapeutic Potential of Complement Inhibition in IgAN

In this activity, an expert in the management of IgA nephropathy (IgAN) explores the multi-hit, complement-mediated hypothesis of IgAN pathogenesis and how emerging targeted therapy may address this complement dysregulation in IgAN disease progression. For the complete activity, including supporting material, please visit: www.peervoice.com/TZX861. Presented by: Jonathan Barratt, PhD, FRCP. Learning Objectives: Describe the relationship between the multi-hit hypothesis and disease trajectory in patients with IgA nephropathy (IgAN); Summarise the role and therapeutic implications of complement pathway dysregulation in IgAN disease progression; Differentiate between emerging therapeutic targets under investigation in patients with IgAN; Interpret data from clinical trials examining emerging therapies, including complement inhibitors, in the context of emerging guidance and approaches to IgAN management.